Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTB-5550 in Select Advanced Solid Tumors
NCT07541573Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2026
- Primary completion
- Jan 2031
- Modality
- Nanobodies (VHH), Trispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GTB-5550 in castration-resistant prostate cancer (CRPC), breast cancer, pancreatic cancer (PC) and 4 more (6 cohorts), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Apr 2026; status: recruiting.
02
Drugs
GTB-5550
03
Conditions
castration-resistant prostate cancer (CRPC)breast cancerpancreatic cancer (PC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07541573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541573.